Compare ACH & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ACH | PRQR |
|---|---|---|
| Founded | 1882 | 2012 |
| Country | United States | Netherlands |
| Employees | 6500 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 217.5M | 244.1M |
| IPO Year | N/A | 2014 |
| Metric | ACH | PRQR |
|---|---|---|
| Price | $3.20 | $1.90 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $3.38 | ★ $7.25 |
| AVG Volume (30 Days) | 567.4K | ★ 863.6K |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.43 | $13.92 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.84 | $1.33 |
| 52 Week High | $4.69 | $3.10 |
| Indicator | ACH | PRQR |
|---|---|---|
| Relative Strength Index (RSI) | 41.54 | 58.12 |
| Support Level | $2.55 | $1.37 |
| Resistance Level | $3.13 | $1.99 |
| Average True Range (ATR) | 0.27 | 0.11 |
| MACD | -0.05 | 0.01 |
| Stochastic Oscillator | 16.88 | 70.59 |
Accendra Health Inc is a nationwide provider of products, technology, and services that support health beyond the hospital by connecting patients, providers, and insurers. Through its brands, Apria and Byram Healthcare, the company delivers disposable medical supplies, integrated home healthcare equipment, and related services that help improve health outcomes and quality of life for individuals with chronic, complex, and acute health conditions. Its offerings span diabetes treatment, home respiratory therapy, and obstructive sleep apnea treatment, along with patient support services. The company also supplies a broad range of home medical equipment and patient care products, including ostomy, wound care, urology, and incontinence solutions.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics. Geographically, the company operates in United States.